Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated AML
NCT00801489Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2007
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of fludarabine, cytarabine, filgrastim, gemtuzumab ozogamicin, idarubicin in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2007; status: recruiting.
02
Drugs
fludarabinecytarabinefilgrastimgemtuzumab ozogamicinidarubicin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00801489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00801489.